Eli Lilly has entered a global research collaboration and licensing agreement with Seamless Therapeutics to develop programmable recombinase-based gene therapies for genetic hearing loss.
Under the deal, Lilly secured exclusive rights to site-specific recombinases programmed by Seamless to target gene mutations associated with hearing loss, according to a Jan. 28 news release from Seamless Therapeutics. The platform enables large, precise DNA insertions independent of natural DNA repair mechanisms.
Seamless is eligible for more than $1.12 billion in development and commercial milestone payments, in addition to upfront and research and development funding. Lilly will lead preclinical and clinical development as well as global commercialization, the release said.
The post Lilly inks $1.1B gene therapy deal for hearing loss appeared first on Becker's Hospital Review | Healthcare News & Analysis.
Source: Read Original Article
